The Hemotransmissive Infections Testing Market is gaining importance as healthcare organizations focus more strongly on preventing transfusion-transmitted infections. The market is projected to grow from USD 2.8 billion in 2025 to USD 8.3 billion by 2035 at an 11.6% CAGR, supported by expanding diagnostic infrastructure, infectious disease awareness, and blood-safety initiatives. 

Testing technologies are moving toward greater automation and molecular precision. Nucleic acid testing enables direct detection of viral genetic material, while automated laboratory systems can increase throughput and standardize sample processing across hospitals, blood banks, and diagnostic facilities. 

The market covers testing for hepatitis B, hepatitis C, and HIV, with HBV DNA testing representing about 40% of market revenue in 2025. The hepatitis B indication segment is also projected to hold the largest share, reflecting continued demand for screening, diagnosis, and monitoring of HBV infections. 

Hospitals remain a major source of testing demand because of blood-transfusion procedures, infection-control requirements, and the need for rapid diagnostic information. North America, Europe, and Asia Pacific are important regional markets, while countries such as China and India are expected to show strong expansion during the forecast period. 

The next phase of market development could focus on integrated testing panels, high-throughput molecular systems, and digital laboratory infrastructure. Combining automation with software-driven workflow management may help laboratories handle growing testing volumes while supporting standardized and efficient screening processes. 